Ebata, Takahiro
Shimizu, Toshio
Fujiwara, Yutaka
Tamura, Kenji
Kondo, Shunsuke
Iwasa, Satoru
Yonemori, Kan
Shimomura, Akihiko
Kitano, Shigehisa
Koyama, Takafumi
Sato, Natsuko
Nakai, Kiyohiko
Inatani, Michiyasu
Yamamoto, Noboru
Funding for this research was provided by:
Chugai Pharmaceutical
Article History
Received: 1 March 2019
Accepted: 25 April 2019
First Online: 24 May 2019
Compliance with ethical standards
:
: Ebata T declares that he has no conflict of interest. Kondo S declares that he has no conflict of interest. Yonemori K declares that he has no conflict of interest. Shimomura A declares that he has no conflict of interest. Koyama T declares that he has no conflict of interest. Yamamoto N is an advisory board member for Eisai, Takeda Pharmaceutical, Otsuka Pharmaceutical, Boehringer Ingelheim, and Cmic Pharma Science, has been involved with sponsored research for Eli Lilly, Abbvie, Janssen Pharmaceutical, MSD, Merck, Quintiles, Astellas Pharma, Chugai Pharmaceutical Co. Ltd., Esai, Taiho, Bristol-Myers Squibb, Pfizer, Novartis Pharma, Daiichi Sankyo, Bayer, Boehringer Ingelheim, Kyowa Hakko Kirin, Takeda Pharmaceutical, and Ono Pharmaceutical, and has received lecture fees from Bristol-Myers Squibb, Pfizer, AstraZeneca, Eli Lilly, Ono Pharmaceutical, and Chugai Pharmaceutical. Shimizu T. has been involved with sponsored research for Bristol-Myers Squibb. Fujiwara Y. is an advisory board member for Bristol-Myers Squibb, Takeda Pharmaceutical, and The Consortium on Harmonization of Institutional Requirements for Clinical Research (CHAIR), Hong Kong, HKSAR and has been involved with sponsored research for Chugai Pharmaceutical Co. Ltd., Incyte Corporation, MSD, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, Novartis Pharma, Eisai, Millenium-Takeda Pharmaceutical, PharmaMar, Five Prime, 3D-Medicine, SymBio Pharmaceuticals and Chordia Therapeutics. Tamura K is an advisory board member for MSD and has been involved with sponsored research for Chugai Pharmaceutical, Bristol-Myers Squibb and MSD. Iwasa S. has been involved with sponsored research for Bristol-Myers Squibb and Chugai Pharmaceutical. Kitano S is an advisory board member for Bristol-Myers Squibb and MSD. Sato N, Nakai K, and Inatani M. are employees of Chugai Pharmaceutical.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study protocol was approved by the Institutional Review Boards of the participating institution.
: Informed consent was obtained from all individual participants included in the study.